Triphenylphosphine-Modified IridiumIII, RhodiumIII, and RutheniumII Complexes to Achieve Enhanced Anticancer Selectivity by Targeting Mitochondria DOI
Zhe Liu,

Hanxiu Fu,

Heqian Dong

и другие.

Inorganic Chemistry, Год журнала: 2024, Номер unknown

Опубликована: Дек. 16, 2024

The incorporation of an organelle-targeting moiety into compounds has proven to be effective strategy in the development targeted anticancer drugs. We herein report synthesis, characterization, and biological evaluation novel triphenylphosphine-modified half-sandwich iridiumIII, rhodiumIII, rutheniumII complexes. primary goal was enhance selectivity through mitochondrial targeting. All these complexes exhibited promising cytotoxicity micromolar range (5.13–23.22) against A549 HeLa cancer cell lines, surpassing activity comparative that lack triphenylphosphine moiety. Noteworthy is their good toward cells compared normal BEAS-2B cells, underscored by index ranging from 7.3 >19.5. Mechanistically, primarily target mitochondria rather than interacting with DNA. targeting triggering dysfunction were confirmed using both confocal microscopy flow cytometry. Their ability depolarize membrane potential (MMP) reactive oxygen species (ROS) observed, thereby leading intrinsic apoptotic pathways. Moreover, lead cycle arrest G2/M phase demonstrated antimigration effects, significantly inhibiting migration wound-healing assays.

Язык: Английский

Nanoparticles in Drug Delivery Systems: Challenges, Innovations, And Surface Modification for Targeted Therapeutics DOI
Tasawar Abbas,

Fatima Kanwar,

Hazima Tariq

и другие.

Indus journal of bioscience research., Год журнала: 2025, Номер 3(1), С. 325 - 336

Опубликована: Янв. 16, 2025

Nanoparticles have become a transforming platform in drug delivery systems. Their remarkable advancement over traditional methods builds upon an improvement bioavailability, stability, and controlled of therapeutic agents. Here, we discuss the broad spectrum potential nanoparticle-based Challenges, innovations, surface modification strategies that affect their clinical translation are discussed. Notwithstanding they present, challenges including biocompatibility, toxicity, targeting efficiency persist restricting extensive utilization. The review emphasizes recent advancements, stimuli-responsive nanoparticles, which provide release reaction to environmental triggers, as well targeted delivery, facilitates selective accumulation agents at designated sites disease. Besides, techniques, such PEGylation, ligand conjugation, charge modulation, been highly promising improving stability reducing immunogenicity, enhancing cellular uptake. future systems based on nanoparticles will address these through new innovations nanoparticle design effect more effective treatments. While research advances, likely bring revolution personalized medicine, tailoring medical therapy for different diseases with minimal side effects better patient outcomes.

Язык: Английский

Процитировано

0

Revolutionizing cellular energy: The convergence of mitochondrial dynamics and delivery technologies DOI
Dilpreet Singh

Mitochondrion, Год журнала: 2024, Номер 76, С. 101873 - 101873

Опубликована: Март 17, 2024

Язык: Английский

Процитировано

2

Nano-based formulations of thymoquinone are new approaches for psoriasis treatment: a literature review DOI Creative Commons
Amir Modarresi Chahardehi,

Hamid Reza Ojaghi,

Hossein Motedayyen

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Авг. 12, 2024

Psoriasis, a persistent immune-mediated inflammatory skin condition, affects approximately 2-3% of the global population. Current treatments for psoriasis are fraught with limitations, including adverse effects, high costs, and diminishing efficacy over time. Thymoquinone (TQ), derived from Nigella sativa seeds, exhibits promising anti-inflammatory, antioxidant, immunomodulatory properties that could prove beneficial in managing psoriasis. However, TQ’s hydrophobic nature poor bioavailability have hindered its usefulness as therapeutic agent. Recent research has strategically addressed these challenges by developing nano-thymoquinone (nano-TQ) formulations to enhance delivery treating Preclinical studies employing mouse models demonstrated nano-TQ effectively mitigates inflammation, erythema, scaling, epidermal thickness, cytokine levels psoriatic lesions. Various formulations, nanoemulsions, lipid vesicles, nanostructured carriers, ethosomes, been explored improve solubility, facilitate penetration, ensure sustained release, achieve site-specific targeting. Although clinical trials currently scarce, outcomes vitro animal promising. The potential co-delivery other anti-psoriatic agents also presents avenues further investigation.

Язык: Английский

Процитировано

1

Triphenylphosphine-Modified IridiumIII, RhodiumIII, and RutheniumII Complexes to Achieve Enhanced Anticancer Selectivity by Targeting Mitochondria DOI
Zhe Liu,

Hanxiu Fu,

Heqian Dong

и другие.

Inorganic Chemistry, Год журнала: 2024, Номер unknown

Опубликована: Дек. 16, 2024

The incorporation of an organelle-targeting moiety into compounds has proven to be effective strategy in the development targeted anticancer drugs. We herein report synthesis, characterization, and biological evaluation novel triphenylphosphine-modified half-sandwich iridiumIII, rhodiumIII, rutheniumII complexes. primary goal was enhance selectivity through mitochondrial targeting. All these complexes exhibited promising cytotoxicity micromolar range (5.13–23.22) against A549 HeLa cancer cell lines, surpassing activity comparative that lack triphenylphosphine moiety. Noteworthy is their good toward cells compared normal BEAS-2B cells, underscored by index ranging from 7.3 >19.5. Mechanistically, primarily target mitochondria rather than interacting with DNA. targeting triggering dysfunction were confirmed using both confocal microscopy flow cytometry. Their ability depolarize membrane potential (MMP) reactive oxygen species (ROS) observed, thereby leading intrinsic apoptotic pathways. Moreover, lead cycle arrest G2/M phase demonstrated antimigration effects, significantly inhibiting migration wound-healing assays.

Язык: Английский

Процитировано

1